Business · 18/10/2002

FDA Reopens Comment Period for Bioavailability and Bioequivalence Testing Guidance

The FDA is extending the comment period for its draft guidance on handling and retention of bioavailability and bioequivalence testing samples until December 17, 2002, in response to industry requests and to provide additional time for public input.